Jyong Biotech Ltd. (MENS) stock
Close on Nov 13, 2026Market cap $133.81MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Dec 31, 2025
Valuation
- Market cap
- $133.81M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$4.67M
- EPS, diluted
- -$0.06
Trading
- Previous close
- $1.68
- Open
- $1.73
- Day's range
- $1.71 – $1.83
- Volume
- 27,029
- Average volume (20 days)
- 41,292
- 52-week range
- $1.43 – $40.25
- RSI (14 days)
- 44.7
- Volatility (1 year)
- 152.5%
- Relative volume
- 0.60×
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | MENS | S&P 500 | Difference | MENS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -13.7% | -3.0% | −10.7 pts | ||
| 3 months | -14.6% | -2.8% | −11.8 pts | ||
| Year to date | -55.4% | +11.5% | −66.9 pts | ||
| 1 year | -95.4% | +13.5% | −108.9 pts |
Four years at a glance
Fiscal years 2022 to 2025, USD
Operating income
Net income
EPS, diluted
Press releases
Releases Jyong Biotech filed with the SEC as exhibits to Form 8-K or 6-K
About Jyong Biotech
Pharmaceutical Preparations
Jyong Biotech Ltd. is a clinical-stage biopharmaceutical company focused on the development of botanical drug products. The company's primary focus is on advancing its core drug candidate, Botreso, which is undergoing clinical development for the initial treatment of benign prostatic hyperplasia and lower urinary tract symptoms (BPH/LUTS). In addition to Botreso, the company explores other potential indications, such as prostate cancer prevention, as well as candidates designated as PCP and IC. Its future customer base encompasses prospective patients, healthcare providers, and third-party payors within the medical community.
Company profile, executives and historyJyong Biotech stock: common questions
What is Jyong Biotech's stock price?
MENS closed at $1.76 on Nov 13, 2026, up 4.76% on the day. Over the past 52 weeks it traded between $1.43 and $40.25.
What is Jyong Biotech's market cap?
Jyong Biotech was worth $133.81M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is MENS's P/E ratio?
Jyong Biotech lost money over fiscal 2025 (diluted EPS -$0.06), so it has no meaningful P/E ratio.
Does Jyong Biotech pay a dividend?
No. Jyong Biotech has not paid a cash dividend over the last twelve months.
How has MENS stock performed over the past year?
Including dividends, MENS returned -95.4% over the past year, against +13.5% for the S&P 500.
How many MENS shares are sold short?
0M shares were sold short at the latest FINRA report, 0.40% of the float, or 5.1 days of average trading volume.
Who are Jyong Biotech's competitors?
Companies most similar to Jyong Biotech by business, industry and size include ANL, NBP, APLM, COGT, PPBT.
See a number that looks wrong?